Searchable abstracts of presentations at key conferences in endocrinology

ea0070oc5.1 | Thyroid | ECE2020

TSH-Independent upregulation of thyroid-specific gene expression in dehal1 knockout mice

Alikhani Pouya , Gonzalez-Guerrero Cristian , Liao Xiao-Hui , Borsò Marco , Peluso Teresa , Zucchi Riccardo , Refetoff Samuel , Moreno Jose Carlos

Background: Most thyroid specific genes are transcriptionally regulated by TSH-TSHR signalling and T4-driven negative feedback of TSH secretion at the pituitary. However, local autoregulation of transcription has been described from IGF-IGFR, follicular thyroglobulin, or iodine. We aimed to investigate the TSH dependency of thyroid transcriptional regulation in the Dehal1 knockout, devoid of iodide-recycling capacity from iodotyrosines.Methods: ...

ea0070aep592 | Pituitary and Neuroendocrinology | ECE2020

Morphometric vertebral fractures are highly prevalent in patients with non-functioning pituitary adenoma and related to older age and hypopituitarism

Frara Stefano , Di Filippo Luigi , Doga Mauro , Maria Formenti Anna , Losa Marco , Resmini Eugenia , Tecilazich Francesco , Mortini Pietro , Giustina Andrea

Introduction: Recent studies showed that morphometric vertebral fractures (VF) are an early and frequent complication in patients (pts) withhyperfunctioning pituitary adenomas and hypopituitarism (independently from the etiology). GH excess or severe deficiency play a negative key role on bone health in this clinical setting. Disease control or adequate replacement therapies still remain a cornerstone for the clinician to reduce the burden of osteo-metabolic complications. To ...

ea0070aep790 | Reproductive and Developmental Endocrinology | ECE2020

Clinical evaluation and genetic analysis of patients affected by premature ovarian insufficiency: Identification and characterization of a new mutation of the BMP-15

Orsolini Francesca , Ferrarini Eleonora , Agretti Patrizia , De Marco Giuseppina , Di Cosmo Caterina , Benelli Elena , Fruzzetti Franca , Tonacchera Massimo

Background: Premature ovarian insufficiency (POI) is an ovarian defect characterized from primary or secondaryamenorrhea, high levels of FSH (> 25 UI/l) and low levels of estrogen, which occurs before age 40.Objective: The aim of the study was to evaluate the clinical features and genetic causes of a group of 68 patients with POI.Methods: We performed anamnestic and clinical evaluation, hormonal and autoimmunity assessment, pel...

ea0070aep880 | Thyroid | ECE2020

Clinical practice survey on BRAF V600E role in the therapeutic decision in indeterminate thyroid cytology

Brigante Giulia , Craparo Andrea , Pignatti Elisa , Marino Marco , Casarini Livio , Sperduti Samantha , Boselli Gisella , Margiotta Gianluca , Rochira Vincenzo , Simoni Manuela

Introduction: The use of multigene panels in thyroid nodule diagnosis is still limited, due to high costs and need for ad hoc sampling. Since BRAF-V600E is the commonest genetic alteration in differentiated thyroid cancer, this is the mostly tested genetic parameter in clinical practice.Aim: To evaluate the use of BRAF mutation analysis in wash-out liquid from fine needle aspiration (FNA) in clinical practice, characterizing th...

ea0070aep1066 | Hot topics (including COVID-19) | ECE2020

Effect of long term rhgh treatment on bone mineral density in patients with childhood onset growth hormone deficiency

Dassie Francesca , Spinazze Alice , Russo Lucia , Parolin Matteo , Mioni Roberto , Maffei Pietro , Zaccaria Marco , Vettor Roberto , De Carlo Eugenio

Background: RhGH treatment in adults with childhood onset growth hormone deficiency (COGHD) affect bone metabolism over time according to gender and age. A long-term study of bone mass density (BMD) in young-middle age hypopituitary patients with COGHD may better highlight possible benefits of therapy and improve clinical follow up.Methods: We enrolled 40 adults (age range during follow-up: 16.8–36 years, F: 38%) with COGHD with at least 20 years o...

ea0032p145 | Calcium and Vitamin D metabolism | ECE2013

Experience in the treatment of primary hyperparathyroidism with cinacalcet: data after 12 months of treatment

Luque-Fernandez Ines , Garcia-Martin Antonia , Luque-Pazos Alessandra , Sastre-Marcos Julia , Vicente-Delgado Almudena , Marco-Martinez Amparo , Canovas Barbara

Introduction: Cinacalcet is an oral calcimimetic indicated in treatment of primary hyperparathyroidism if patients do not accept surgery, do not carry out the surgical criteria, there is failure of previous surgery or serious comorbidity that makes surgery impossible.Methods: Descriptive study that included 20 patients with primary hyperparathyroidism who had complete at least 12 months of treatment with cinacalcet for different reasons (eight patients r...

ea0032p467 | Diabetes | ECE2013

Efficacy and safety of 1 year treatment with Liraglutide in subjects with type 2 diabetes

Prodam Flavia , Zavattaro Marco , Ponziani Chantal , Pagano Loredana , Caputo Marina , Allochis Gabriele , Teresa Sama Maria , Busti Arianna , Aimaretti Gianluca

Introduction: Liraglutide, a GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the efficacy and safety of liraglutide in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). All patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatment, or patients intole...

ea0032p473 | Diabetes | ECE2013

Cardiovascular effects of treatment with Liraglutide in a population with type 2 diabetes

Zavattaro Marco , Prodam Flavia , Grazia Mauri Maria , Pagano Loredana , Caputo Marina , Belcastro Sara , Allochis Gabriele , Aimaretti Gianluca

Introduction: Liraglutide, a human GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the effects of liraglutide on cardiovascular risk factors in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). Patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatmen...

ea0032p552 | Endocrine tumours and neoplasia | ECE2013

Androgen receptor expression in stromal and epithelial prostate cancer tissue specimens

Lara Tamburrino , Francesca Salvianti , Sara Marchiani , Gabriella Nesi , Michele Lanciotti , Marco Carini , Pamela Pinzani , Elisabetta Baldi , Gianni Forti

Prostate cancer (PCa) is one of the leading causes of tumor death in Western countries. Modifications in expression and functional alterations that involve the androgen receptor (AR) have been implicated in the progression of PCa and in the development of androgen independence; however, the role of AR in these processes is still debated, as contrasting results have been reported in several studies evaluating the relation between AR expression and disease progression (Tamburrin...

ea0032p640 | Male reproduction | ECE2013

Complete aromatase deficiency in four adult men: detection of a novel mutation and two known mutations in the CYP19A1 gene

Pignatti Elisa , Unluhizarci Kursad , Kartal Ermine , Ajlouni Kamel , Khawaja Nahla , Carani Cesare , Marino Marco , Simoni Manuela , Vighi Eleonora , Rochira Vincenzo

Introduction: At present, only eight men with loss-of-function mutations in the CYP19A1 gene have been described. Here we report the genetic study of four adult men with undetectable serum estrogens, unfused epiphyses, eunuchoid skeletal proportions, continuing linear growth, tall stature, genu valgum, osteoporosis, obesity and achantosis nigricans. Patient 1 (26-years/182 cm) and 2 (28-years/187 cm) are from Turkey with a history of consanguinity. Patient 3 (44-years...